PMID- 37698765
OWN - NLM
STAT- MEDLINE
DCOM- 20231110
LR  - 20231111
IS  - 2190-3883 (Electronic)
IS  - 1234-1983 (Print)
IS  - 1234-1983 (Linking)
VI  - 64
IP  - 4
DP  - 2023 Dec
TI  - Modern therapies of nonsmall cell lung cancer.
PG  - 695-711
LID - 10.1007/s13353-023-00786-4 [doi]
AB  - Lung cancer (LC), particularly nonsmall cell lung cancer (NSCLC), is one of the 
      most prevalent types of neoplasia worldwide, regardless of gender, with the 
      highest mortality rates in oncology. Over the years, treatment for NSCLC has 
      evolved from conventional surgery, chemotherapy, and radiotherapy to more 
      tailored and minimally invasive approaches. The use of personalised therapies has 
      increased the expected efficacy of treatment while simultaneously reducing the 
      frequency of severe adverse effects (AEs). In this review, we discuss established 
      modern approaches, including immunotherapy and targeted therapy, as well as 
      experimental molecular methods like clustered regularly interspaced short 
      palindromic repeat (CRISPR) and nanoparticles. These emerging methods offer 
      promising outcomes and shorten the recovery time for various patients. Recent 
      advances in the diagnostic field, including imaging and genetic profiling, have 
      enabled the implementation of these methods. The versatility of these modern 
      therapies allows for multiple treatment options, such as single-agent use, 
      combination with existing conventional treatments, or incorporation into new 
      regimens. As a result, patients can survive even in the advanced stages of NSCLC, 
      leading to increased survival indicators such as overall survival (OS) and 
      progression-free survival (PFS).
CI  - (c) 2023. The Author(s).
FAU - Jachowski, Andrzej
AU  - Jachowski A
AD  - Department of Biochemistry and Molecular Biology, Poznan University of Medical 
      Sciences, Swiecickiego 6 Street, 60-781, Poznan, Poland.
FAU - Marcinkowski, Mikolaj
AU  - Marcinkowski M
AD  - Department of Biochemistry and Molecular Biology, Poznan University of Medical 
      Sciences, Swiecickiego 6 Street, 60-781, Poznan, Poland.
FAU - Szydlowski, Jakub
AU  - Szydlowski J
AD  - Department of Biochemistry and Molecular Biology, Poznan University of Medical 
      Sciences, Swiecickiego 6 Street, 60-781, Poznan, Poland.
FAU - Grabarczyk, Oskar
AU  - Grabarczyk O
AD  - Department of Biochemistry and Molecular Biology, Poznan University of Medical 
      Sciences, Swiecickiego 6 Street, 60-781, Poznan, Poland.
FAU - Nogaj, Zuzanna
AU  - Nogaj Z
AD  - Department of Biochemistry and Molecular Biology, Poznan University of Medical 
      Sciences, Swiecickiego 6 Street, 60-781, Poznan, Poland.
FAU - Marcin, Laz
AU  - Marcin L
AD  - Department of Biochemistry and Molecular Biology, Poznan University of Medical 
      Sciences, Swiecickiego 6 Street, 60-781, Poznan, Poland.
FAU - Plawski, Andrzej
AU  - Plawski A
AD  - Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska 32 Street, 
      60-479, Poznan, Poland.
FAU - Jagodzinski, Pawel Piotr
AU  - Jagodzinski PP
AD  - Department of Biochemistry and Molecular Biology, Poznan University of Medical 
      Sciences, Swiecickiego 6 Street, 60-781, Poznan, Poland.
FAU - Slowikowski, Bartosz Kazimierz
AU  - Slowikowski BK
AUID- ORCID: 0000-0002-6547-486X
AD  - Department of Biochemistry and Molecular Biology, Poznan University of Medical 
      Sciences, Swiecickiego 6 Street, 60-781, Poznan, Poland. 
      slowikowski.bartek@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230912
PL  - England
TA  - J Appl Genet
JT  - Journal of applied genetics
JID - 9514582
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy
MH  - *Lung Neoplasms/genetics/therapy
MH  - Immunotherapy/methods
PMC - PMC10632224
OTO - NOTNLM
OT  - CRISPR
OT  - Immunotherapy
OT  - Lung cancer
OT  - NSCLC
OT  - Nanoparticles
OT  - Targeted therapy
COIS- The authors declare no competing interests.
EDAT- 2023/09/12 12:41
MHDA- 2023/11/10 06:45
PMCR- 2023/09/12
CRDT- 2023/09/12 11:22
PHST- 2023/06/21 00:00 [received]
PHST- 2023/09/01 00:00 [accepted]
PHST- 2023/09/01 00:00 [revised]
PHST- 2023/11/10 06:45 [medline]
PHST- 2023/09/12 12:41 [pubmed]
PHST- 2023/09/12 11:22 [entrez]
PHST- 2023/09/12 00:00 [pmc-release]
AID - 10.1007/s13353-023-00786-4 [pii]
AID - 786 [pii]
AID - 10.1007/s13353-023-00786-4 [doi]
PST - ppublish
SO  - J Appl Genet. 2023 Dec;64(4):695-711. doi: 10.1007/s13353-023-00786-4. Epub 2023 
      Sep 12.